Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2005

View Archived Issues

New and potent non-nucleoside inhibitors of wild-type and mutant reverse transcriptases

Tripep reports on ChronVac developments

Phase II study assesses 17-AAG for Von Hippel-Lindau disease

Aplidin enters phase II for prostate and bladder cancers

Preclinical results from EntreMed's PAR-2 inhibitor program

Memory adds PDE10A inhibitor program to pipeline

Enrollment completed in phase II colorectal cancer study of HGS-ETR1

Kaken launches GHRP Kaken 100 in Japan

Sosei inlicenses urology drug from Otsuka

Triple inhibitors tested for the treatment of cardiovascular and renal diseases / News in Context

Millenia Hope studies MMH-8 Malarex in new pediatric study

New indication approved for pazufloxacin mesilate in Japan

Transgene has new strategy in therapeutic vaccines

Kissei presents new beta3-adrenoceptor agonists

Sodium-glucose cotransporter inhibitors jointly reported by Yamanouchi and Kotobuki

Novel antifungal agents discovered by SSP

European approval for Truvada

Roche discloses new mGluR5 receptor antagonists for anxiety and pain

Fuji Photo Film announces pyranose derivatives for use in X-ray contrast media

Pegasys approved for hepatitis B in Europe

Novel Raf kinase inhibitors claimed by Novartis for the treatment of cancer

Daiichi Pharmaceutical and Sankyo to integrate businesses

Pfizer discloses cannabinoid CB1 receptor antagonists for treating obesity and alcohol dependence

Clinical trials evaluate the antiviral effects and safety of PA-457 in HIV infection

Promising effects found with an amdoxovir/enfuvirtide regimen in HIV infection

Good safety profile reported for 640385 in healthy volunteers

Add-on capravirine enhances the efficacy of a standard-of-care antiretroviral regimen

Phase I data on the toxicity of BAY-43-9006 in patients with advanced solid tumors

Cizolirtine enters phase II for stress urinary incontinence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...